The National Agency for Food and Drug Administration and Control (NAFDAC) has warned the public about an unregistered Gold Vision Oxytocin Injection 10IU bearing a fake registration number.
The alert, numbered 028/2025, was published on the agency’s official website.
According to NAFDAC, the product was falsely labelled as manufactured by Anhui Hongye Pharmaceutical Co., Ltd., Fengyang East Road, Bengbu, Anhui Province, China, and marketed by Gold Vision Medicals, No. 4 Range Avenue, Independence Layout, Enugu, Nigeria.
The agency said the falsified product was discovered during a risk-based sampling survey conducted by officers of its Post-Marketing Surveillance (PMS) Directorate. Further investigations also revealed three other falsified products A-tocin Injection, Extocin Injection, and Claxitodin Injection all bearing the same forged registration number, A4-9566, and purportedly from the same manufacturer.
NAFDAC confirmed that these products are not listed in its registered products database.
Also Read:Â NAFDAC Intercepts Expired Beverages Worth N35m in Kaduna
Oxytocin, a natural hormone available as a drug, is commonly used to induce or strengthen labour, control postpartum bleeding, and support lactation. NAFDAC warned that using falsified or unregistered oxytocin injections poses severe risks to both mothers and newborns, including ineffective contractions, postpartum haemorrhage, or maternal death. Poor-quality oxytocin could also delay or prevent bleeding control after childbirth, potentially requiring emergency interventions such as blood transfusion or surgery.
The agency directed its zonal directors and state coordinators to monitor and withdraw such falsified products nationwide. It urged importers, distributors, retailers, healthcare professionals, and consumers to remain vigilant, ensuring that all medicines and medical devices are sourced only from licensed suppliers and properly verified.
NAFDAC encouraged the public to report suspicions of substandard or falsified medicines and medical devices to the nearest NAFDAC office, via its toll-free number 0800-162-3322, or by email at sf.alert@nafdac.gov.ng. Reports of adverse effects should also be submitted through NAFDAC offices, its e-reporting platforms on www.nafdac.gov.ng, the Med-safety app (Android and iOS), or via email at pharmacovigilance@nafdac.gov.ng.
